Vodobatinib

Vodobatinib (K0706) is a potent, third generation and orally active Bcr-Abl1 tyrosine kinase inhibitor with an IC50 of 7 nM. Vodobatinib exhibits activity against most BCR-ABL1 point mutants, and has no activity against BCR-ABL1T315I. Vodobatinib can be used for chronic myeloid leukemia (CML) research[1][2]. Vodobatinib is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.


Cat. No.: EX-A6146	Purity: >98%

	Chemical structure of Vodobatinib

For research only, Do not use for Human!

Size	Unit Price (US$)	Stock
250mg	get quote	Inqure
500mg	get quote	Inqure
1g	get quote	Inqure
5g	get quote	Inqure

Send PO to E-mail:[email protected]; or Fax:+86 020 81619670

Discount Request


Synonyms	K0706
CAS No.	1388803-90-4
Purity	>98%
Formula	C27H20ClN3O2
Mol Weight	453.92
Color	White to off-white
State	solid powder
Solubility	Soluble in DMSO 125 mg/mL
Shelf Life	>3 years if stored properly
Storage	Powder -20°C 3 years, 4°C 2 years; In solvent -20℃ 1 month;
Shipping	Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Reference:	[1]. Orlando Antelope, et al. BCR-ABL1 tyrosine kinase inhibitor K0706 exhibits preclinical activity in Philadelphia chromosome-positive leukemia. Exp Hematol. 2019 Sep;77:36-40.e2. [2]. Phase 1 Trial of Vodobatinib, a Novel Oral BCR-ABL1 Tyrosine Kinase Inhibitor (TKI): Activity in CML Chronic Phase Patients Failing TKI Therapies Including Ponatinib. Session: 632: Chronic Myeloid Leukemia: Therapy: CML: New and Beyond.
CoA	CoA of Vodobatinib


		Search